This clinical perspective argues that in primary aldosteronism (PA), normalizing plasma renin—rather than focusing solely on blood pressure and serum potassium—should be considered a key therapeutic target. Persistent renin suppression under mineralocorticoid receptor antagonist (MRA) therapy may signal ongoing aldosterone excess and residual cardiometabolic risk, even when office blood pressure appears controlled. The authors propose that titrating MRA doses to achieve renin “unsuppression” could better mitigate long‑term vascular and renal damage, while highlighting the need for prospective studies to define safe, evidence‑based renin targets in PA. To learn more Click Here ##Reference## Fay KS, Hundemer GL, Vaidya A. Primary aldosteronism and plasma renin targets.
Lancet Diabetes Endocrinol. 2025;13(12):992‑993. doi:10.1016/S2213-8587(25)00301-8.## In your experience, what would…
